Nuvation Bio

Nuvation Bio is a late clinical-stage, global biopharmaceutical company dedicated to treating patients with difficult-to-treat cancers for which conventional therapies have failed. The company focuses on developing differentiated and novel product candidates, primarily generated through their proprietary drug discovery and development programs and acquired through strategic business development activities. Nuvation Bio was founded in 2018 by David Hung, M.D., a seasoned biopharma industry leader with a proven track record of success, previously founding Medivation Inc., which brought to patients one of the world’s leading prostate cancer medicines.

The company boasts a robust pipeline of oncology drug candidates, including taletrectinib (ROS1 inhibitor), safusidenib (mIDH1 inhibitor), NUV-1511 (drug-drug conjugate), and NUV-868 (BET inhibitor). Nuvation Bio is advancing these candidates through clinical trials and aims to significantly change the practice of oncology by developing medicines that provide truly meaningful improvements in quality of life and survival for people with cancer.

Nuvation Bio is a late clinical-stage, global biopharmaceutical company dedicated to treating patients with the most challenging cancers for which conventional therapies have failed. Their vision is to revolutionize oncology by developing new medicines that meaningfully improve quality of life and survival for cancer patients, addressing drug resistance and limited efficacy of current therapies while minimizing side effects. Nuvation Bio focuses on developing and commercializing novel therapies specifically targeting indications where conventional treatments have proven ineffective.

Nuvation Bio promotes a culture of innovation, collaboration, and commitment to developing life-changing oncology therapies. The company values its employees' diverse expertise, fostering a supportive environment that encourages open communication and teamwork. With a focus on tackling challenging oncology needs, Nuvation Bio emphasizes a driven and results-oriented approach, while also prioritizing a strong sense of purpose and dedication to improving patients' lives.